Hologic (NASDAQ:HOLX) Given New $90.00 Price Target at Mizuho

Hologic (NASDAQ:HOLX) had its target price upped by Mizuho from $85.00 to $90.00 in a research note released on Friday morning, Benzinga reports. Mizuho currently has an outperform rating on the medical equipment provider’s stock.

A number of other brokerages also recently issued reports on HOLX. JPMorgan Chase & Co. raised their price objective on Hologic from $91.00 to $95.00 and gave the stock an overweight rating in a research report on Tuesday, July 30th. Citigroup downgraded shares of Hologic from a buy rating to a neutral rating and dropped their price target for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Royal Bank of Canada restated a sector perform rating and set a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Evercore ISI raised their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an in-line rating in a report on Tuesday, October 1st. Finally, Needham & Company LLC restated a buy rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $87.27.

Hologic Price Performance

HOLX stock opened at $79.88 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The business has a 50 day simple moving average of $81.28 and a 200-day simple moving average of $77.48. The firm has a market capitalization of $18.64 billion, a PE ratio of 40.76, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic has a 1 year low of $64.02 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the firm posted $0.93 earnings per share. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. Equities research analysts anticipate that Hologic will post 4.09 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,280 shares of company stock worth $1,469,973. Company insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

Hedge funds and other institutional investors have recently modified their holdings of the stock. Massmutual Trust Co. FSB ADV grew its holdings in Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the last quarter. Graypoint LLC raised its holdings in shares of Hologic by 3.9% in the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after purchasing an additional 147 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 165 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Hologic by 0.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock valued at $2,425,000 after acquiring an additional 192 shares in the last quarter. Finally, Curbstone Financial Management Corp lifted its stake in shares of Hologic by 0.9% during the second quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider’s stock worth $1,717,000 after purchasing an additional 200 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.